Centessa Pharmaceuticals plc

NASDAQ•CNTA

CEO: Dr. Saurabh Saha M.D., Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2021-05-28

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Contact Information

1 Ashley Road, 3rd Floor, Altrincham, WA14 2DT, United Kingdom

N/A

www.centessa.com

Market Cap

$3.79B

P/E (TTM)

-15.6

17.4

Dividend Yield

52W High

$30.58

52W Low

$9.60

52W Range

89%

Rank73Top 99.9%

0.8

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 0.8 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.41+10.81%

4-Quarter Trend

FCF

-$58.55M+173.29%

4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Genmab License Revenue Recognized Recognized $15.0M upfront revenue from Genmab License Agreement in Q1 2025, boosting nine-month revenue.

R&D Investment Ramps Up R&D expenses increased $33.3M to $117.7M for nine months, focusing on OX2R agonist pipeline advancement.

Cash Position Maintained Cash, equivalents, and investments totaled $349.0M as of September 30, 2025, funding operations into mid-2027.

ORX142 Clinical Advancement Initiated Phase 1 FIH clinical trial for ORX142, the second OX2R agonist candidate, following IND clearance in June 2025.

Risk Factors

Net Loss Widens Nine-month net loss increased to $(131.4M) from $(124.4M) due to higher R&D costs and program termination expenses.

Operating Cash Usage Rises Net cash used in operating activities rose to $(138.0M) for nine months, reflecting $28.3M in program termination payments made.

Development Success Uncertain Product candidates face high failure rates; success hinges on demonstrating safety and efficacy in ongoing clinical trials.

Need for Capital Substantial additional capital required to fund ongoing operations and expected increased expenses into mid-2027.

Outlook

ORX750 Dose Selection Planned Expect Phase 2a study results to enable dose selection for the registrational program targeted for the first quarter of 2026.

Pipeline Candidates Advancing Planning patient studies for ORX142 in Q1 2026; ORX489 is currently in IND-enabling studies.

Future Financing Anticipated Anticipate needing substantial additional funding to support ongoing development activities and expected commercialization expenses.

Prioritizing OX2R Franchise Strategic decision made to prioritize capital towards the development of the growing OX2R agonist franchise.

Peer Comparison

Revenue (TTM)

LEGN

$1.03B

+64.2%

APLS

$1.00B

+28.5%

RARE

$672.72M

+20.1%

Gross Margin (Latest Quarter)

SLNO

99.1%

+0.0pp

RARE

86.0%

-2.4pp

APLS

85.1%

+11.7pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
CDTX	$5.61B	-18.6	-60.1%	0.4%
CGON	$5.46B	-31.0	-22.9%	0.9%
CELC	$5.36B	-31.9	-179.0%	67.3%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Mar 23, 2026

EPS:-$0.37

Revenue:$708.00K

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data